SCHEMBL5822713

SCHEMBL5822713

CC(C)C(C)(Oc1cccc2ccccc12)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.68
▸ KDM4E B2RXH2 4/20 0.68
▸ HSD17B10 Q99714 2/20 0.68
▸ PPARG P37231 7/20 0.48
▸ PPARA Q07869 7/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ PPARD Q03181 1/20 0.48
▸ HPGD P15428 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ PGR P06401 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ NR2E1 Q9Y466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5822854 0.81 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL2961689 0.80 ALDH1A1 (0.73) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL5821718 0.75 CYP1A2 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL24361889 0.74 ALDH1A1 (0.66) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL11991243 0.74 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10HPGDTDP1
SCHEMBL1357247 0.73 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10HPGDTDP1
SCHEMBL1357250 0.73 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10CYP2C19HPGD
SCHEMBL2668311 0.73 ALDH1A1 (0.73) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9787249 0.73 ALDH1A1 (0.73) ALDH1A1KDM4EHSD17B10PPARGPPARA
Methacrylic Acid SCHEMBL16660496 0.73 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006058199-A1 METHODS OF MODULATING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND PHARMACEUTICAL FORMULATIONS FOR THE SAME FAZIX CORPORATION (US) 2006-06-01 — — WO disclosed
US-20060111346-A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same FAZIX CORPORATION. 2006-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111346-A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same HDLBP, LDLR, CETP ALDH1A1 3198/4885KDM4E 2223/4885HSD17B10 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback